血红蛋白水平与静脉羧基麦芽糖铁在急性心衰合并缺铁患者中疗效的关联:AFFIRM-AHF亚组分析
AFFIRM-AHF预设亚组分析按基线血红蛋白<12 vs ≥12 g/dL分层,评估静脉羧基麦芽糖铁(FCM)对急性心衰合并缺铁患者52周结局的影响。主要复合终点年化事件率在<12 g/dL组为FCM 71.1 vs 安慰剂73.6(RR 0.97 [95%CI 0.66-1.41]),≥12 g/dL组为48.5 vs 72.9(RR 0.67 [95%CI 0.48-0.93]),交互作用P=0.15。结论:FCM对结局及铁参数改善的效应在两组间无显著差异。
要点
- FCM对主要复合终点的效应在血红蛋白<12与≥12 g/dL组间无显著交互作用(P=0.15)。
- 血红蛋白≥12 g/dL组主要复合终点RR 0.67(95%CI 0.48-0.93),<12 g/dL组RR 0.97(95%CI 0.66-1.41)。
- FCM改善铁参数(血红蛋白、铁蛋白、转铁蛋白饱和度)的效应在两组均显著。
核心结论
- 静脉FCM对急性心衰稳定后缺铁患者结局及铁参数改善的效应在血红蛋白<12与≥12 g/dL组间无显著差异。
研究设计与样本
- AFFIRM-AHF为多中心、双盲、随机、安慰剂对照试验,纳入因急性心衰住院且缺铁的1108例患者,本亚组分析纳入1107例。
- 按基线血红蛋白<12 vs ≥12 g/dL分层,比较FCM与安慰剂在第52周的主要复合终点(总心衰住院和心血管死亡)及次要终点。
主要发现
- 血红蛋白<12 g/dL组464例(FCM 228,安慰剂236),≥12 g/dL组643例(FCM 329,安慰剂314)。
- 主要复合终点年化事件率/100患者年:<12 g/dL组FCM 71.1 vs 安慰剂73.6(RR 0.97 [95%CI 0.66-1.41]);≥12 g/dL组FCM 48.5 vs 安慰剂72.9(RR 0.67 [95%CI 0.48-0.93])。
- 主要(Pinteraction=0.15)及次要终点均无显著血红蛋白亚组与治疗交互作用。
- 第6至52周血红蛋白、血清铁蛋白和转铁蛋白饱和度较基线变化在两组中FCM均显著大于安慰剂。
- 采用WHO贫血定义(女性<12 g/dL、男性<13 g/dL)敏感性分析结果相似。
临床怎么用
- 对急性心衰稳定后缺铁患者,无论血红蛋白是否<12 g/dL,均可考虑静脉FCM以改善铁参数。
- 血红蛋白≥12 g/dL者可能从FCM中获得主要复合终点获益(RR 0.67),但需注意交互作用未达统计学显著。
局限性
- 原文未报告亚组分析的具体局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Iron deficiency, with or without anemia, is an adverse prognostic factor in heart failure (HF). In AFFIRM-AHF (a randomized, double-blind placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalizations and mortality in iron-deficient subjects admitted for acute heart failure), intravenous ferric carboxymaltose (FCM), although having no significant effect on the primary end point, reduced the risk of HF hospitalization (hHF) and improved quality of life versus placebo in iron-deficient patients stabilized after an acute HF (AHF) episode. These prespecified AFFIRM-AHF subanalyses explored the association between hemoglobin levels and FCM treatment effects. METHODS: AFFIRM-AHF was a multicenter, double-blind, randomized, placebo-controlled trial of FCM in hospitalized AHF patients with iron deficiency. Patients were stratified by baseline hemoglobin level (<12 versus ≥12 g/dL). In each subgroup, the primary composite (total hHF and cardiovascular death) and secondary (total hHF; total cardiovascular hospitalizations and cardiovascular death; time to cardiovascular death, and time to first/days lost due to hHF or cardiovascular death) outcomes were assessed with FCM versus placebo at week 52. Sensitivity analyses using the World Health Organization anemia definition (hemoglobin level <12 g/dL [women] or <13 g/dL [men]) were performed, among others. RESULTS: Of 1108 AFFIRM-AHF patients, 1107 were included in these subanalyses: 464 (FCM group, 228; placebo group, 236) had a hemoglobin level <12 g/dL, and 643 (FCM, 329; placebo, 314) had a hemoglobin level ≥12 g/dL. Patients with a hemoglobin level <12 g/dL were older (mean, 73.7 versus 69.1 years), with more frequent previous HF (75.0% versus 68.7%), serum ferritin <100 μg/L (75.4% versus 68.1%), and transferrin saturation <20% (87.9% versus 81.4%). For the primary outcome, annualized event rates per 100 patient-years with FCM versus placebo were 71.1 and 73.6 (rate ratio, 0.97 [95% CI, 0.66-1.41]), respectively, and 48.5 versus 72.9 (RR, 0.67 [95% CI, 0.48-0.93]) in the hemoglobin levels <12 and ≥12 g/dL subgroups, respectively. No significant interactions between hemoglobin subgroup and treatment effect were observed for primary (Pinteraction=0.15) or secondary outcomes. Changes from baseline in hemoglobin, serum ferritin and transferrin saturation were significantly greater with FCM versus placebo in both subgroups between weeks 6 and 52. Findings were similar using the World Health Organization definition for anemia. CONCLUSIONS: The effects of intravenous FCM on outcomes in iron-deficient patients stabilized after an AHF episode, including improvements in iron parameters over time, did not differ between patients with hemoglobin levels <12 and ≥12 g/dL. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT02937454.
引用
- Filippatos, Ponikowski, Farmakis, et al. Association Between Hemoglobin Levels and Efficacy of Intravenous Ferric Carboxymaltose in Patients With Acute Heart Failure and Iron Deficiency: An AFFIRM-AHF Subgroup Analysis. Circulation. 2023. PMID: 37051919. doi:10.1161/CIRCULATIONAHA.122.060757
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。